Yinan Lin, PhD

Yinan Lin advises life sciences companies on intellectual property strategy and transactions, with a particular focus on complex IP structuring, portfolio management, and strategic agreements. She works with pharmaceutical and biotechnology clients across the full innovation lifecycle—from early-stage research through clinical development, manufacturing, and commercialization—drawing on scientific fluency, patent experience, and transactional insight.

With advanced training in chemistry and biomedical sciences, Yinan brings a thoughtful approach to protecting innovation in the life sciences. She has developed and implemented IP strategies for a range of therapeutic programs, including small molecules, biologics, and gene therapies.

Her deal experience includes IP licensing and asset acquisitions, license terminations and program divestitures, mergers and business acquisitions, R&D collaborations, supply chain and distribution agreements, and other commercial agreements supporting business operations, financing, partnering, monetization, and broader strategic goals.

Licensing & Collaboration:

• Patent and technology license negotiations with a major U.S. cancer research center for a clinical-stage biotech company.
• Multi-target collaboration and license agreement for access to a biotech’s proprietary drug candidate screening platform for a U.S.-headquartered global pharmaceutical company.
• Termination of a clinical development program involving joint licensors and a territorial division with a foreign co-licensee for a global biotech company.
•  Development of a form in-license agreement to streamline partnerships and support portfolio growth for a biotech investment company.

IP & Corporate Restructuring:

• Corporate reorganization involving asset- and program-specific spin-outs for a clinical-stage biopharmaceutical company, addressing IP, in- and out-licensing, and supply chain arrangements.
• Licensing and technology transfer in the acquisition of clinical- and commercial-stage assets from a former licensor undergoing bankruptcy restructuring for a cross-border biotech company.

M&A / Asset Acquisitions:

• IP and contract aspects of the acquisition of a U.S. clinical-stage immunotherapy company for a leading global life science company.
• IP and contract aspects of the acquisition of a late-stage clinical development program from Asia for a multi-national biotech company.
• Manufacturing and transition services agreements in the global divestiture of a commercial therapeutic product to a U.S. public company for a multi-national pharmaceutical company.